These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 11015024

  • 1. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara I, Takahashi Y, Tanaka A, Koide H.
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract] [Full Text] [Related]

  • 2. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.
    Am J Nephrol; 2000 Oct; 20(5):373-9. PubMed ID: 11092994
    [Abstract] [Full Text] [Related]

  • 3. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K, Christensen PK, Jensen BR, Parving HH.
    Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
    [Abstract] [Full Text] [Related]

  • 4. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
    Franke H.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
    [No Abstract] [Full Text] [Related]

  • 5. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S, Stirling AL.
    Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259
    [Abstract] [Full Text] [Related]

  • 6. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
    Zanchetti A, Omboni S, Di Biagio C.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S57-9. PubMed ID: 9331009
    [No Abstract] [Full Text] [Related]

  • 7. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 8. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, Yamamoto K, Kato T, Hayakawa N, Oda N, Goto Y, Goto Y, Nagasaka A, Senda T, Itoh M.
    Horm Metab Res; 2004 Jul 11; 36(7):458-64. PubMed ID: 15305228
    [Abstract] [Full Text] [Related]

  • 9. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep 11; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 10. Tolerability of a modern antihypertensive agent: candesartan cilexetil.
    Andersson OK.
    Basic Res Cardiol; 1998 Sep 11; 93 Suppl 2():54-8. PubMed ID: 9833164
    [Abstract] [Full Text] [Related]

  • 11. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 12. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G, Fuchs W.
    Curr Med Res Opin; 2005 Jun 09; 21(6):935-40. PubMed ID: 15969893
    [Abstract] [Full Text] [Related]

  • 13. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
    Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M.
    Hypertens Res; 2003 Jun 09; 26(6):453-8. PubMed ID: 12862201
    [Abstract] [Full Text] [Related]

  • 14. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
    Haneda M, Kikkawa R, Sakai H, Kawamori R, Candesartan in Diabetic Nephropathy Study Group.
    Diabetes Res Clin Pract; 2004 Oct 09; 66(1):87-95. PubMed ID: 15364166
    [Abstract] [Full Text] [Related]

  • 15. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 1997 Aug 09; 55(8):2075-80. PubMed ID: 9284426
    [Abstract] [Full Text] [Related]

  • 16. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y, Ogihara T.
    Am J Hypertens; 2005 Jan 09; 18(1):13-7. PubMed ID: 15691611
    [Abstract] [Full Text] [Related]

  • 17. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
    Heuer HJ, Schöndorfer G, Högemann AM.
    J Hum Hypertens; 1997 Sep 09; 11 Suppl 2():S55-6. PubMed ID: 9331008
    [No Abstract] [Full Text] [Related]

  • 18. Blocking the tissue renin-angiotensin system: the future cornerstone of therapy.
    Unger T, Azizi M, Belz GG.
    J Hum Hypertens; 2000 Oct 09; 14 Suppl 2():S23-31. PubMed ID: 11086633
    [Abstract] [Full Text] [Related]

  • 19. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec 09; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 20. Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
    Matsuo T, Ishikawa E, Ohta M, Shibouta Y, Ishimura Y, Imura Y, Sugiyama Y.
    Jpn J Pharmacol; 2002 Mar 09; 88(3):300-6. PubMed ID: 11949885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.